Biogen (BIIB) vs Amgen (AMGN) and Gilead (GILD): Which Big Pharma Stock is a Better Buy?
Biogen Inc. (NASDAQ:BIIB) closed at $225.71 on October 9.
Gilead Sciences Inc. (GILD)
Market is closed
Hedge Fund Popularity
Hedge Fund Holdings
Filing Period: Filing is Ongoing
Last updated on based on SEC 13F filings Last update:
| No. | Hedge Fund | Shares | Value | Activity | % Port |
|---|---|---|---|---|---|
| 1. | Bailard Inc Thomas Bailard | 734,720 | $109,510,135 | +1% | 2.22% |
| 2. | Sivik Global Healthcare Krishen Sud | 25,000 | $3,726,250 | 2.13% |
Insider Trading: Purchases See All
| Insider | Price | Amount | Total Value | Remaining Holdings | Date | Form 4 |
|---|---|---|---|---|---|---|
| $99.92 | 10,000 | $999,150.00 | 88,173 | 2015-02-06 | Filing | |
| $43.05 | 10,000 | $430,493.00 | 69,458 | 2013-02-28 | Filing | |
| $44.00 | 10,000 | $439,955.00 | 26,097 | 2012-02-22 | Filing | |
| $38.60 | 8,704 | $335,974.40 | 12,800 | 2010-05-04 | Filing | |
| $38.59 | 4,096 | $158,064.64 | 4,096 | 2010-05-04 | Filing |
Insider Trading: Sales See All
| Insider | Price | Amount | Total Value | Remaining Holdings | Date | Form 4 |
|---|---|---|---|---|---|---|
| $156.22 | 3,000 | $468,660.00 | 161,096 | 2026-10-15 | Filing | |
| $156.22 | 3,000 | $468,660.00 | 113,684 | 2026-10-15 | Filing | |
| $148.63 | 3,000 | $445,879.50 | 566,683 | 2026-10-01 | Filing | |
| $147.72 | 12,000 | $1,772,628.00 | 569,683 | 2026-10-01 | Filing | |
| $145.29 | 3,000 | $435,870.00 | 164,096 | 2026-09-15 | Filing |
Institutional Investors' Holdings
Filing Period: Filing is Ongoing
| No. | Name | Shares | Value | % Port |
|---|---|---|---|---|
| 1. | 1,560,454 | $232,585,669 | 0.23% | |
| 2. | 791,297 | $117,942,892 | 1.98% | |
| 3. | 702,082 | $104,645,321 | 0.38% | |
| 4. | 558,657 | $83,267,826 | 0.43% | |
| 5. | 356,269 | $53,101,894 | 0.28% |
News See All
Can Gilead (GILD) Stock Continue Rising in 2027?
Gilead Sciences, Inc. (NASDAQ:GILD) shares are up more than 24% this year, ahead of the S&P 500’s 14%. Gilead makes HIV, liver disease and cancer drugs.
Claude AI Portfolio: 8 Best-Performing Stocks in 2026
The use of AI for stock picking among retail and institutional investors is rising.
Gilead Has Outperformed the S&P 500. But is its Valuation Still Attractive?
Gilead Sciences, Inc. (NASDAQ:GILD) has had a considerably better year than the broader market.
Can Lenacapavir Power Gilead Sciences (GILD)’s Next Growth Phase?
On September 16, Gilead Sciences, Inc.
Gilead vs. Intuitive Surgical: Which Healthcare Stock Offers the Better Risk-Adjusted Upside?
At first glance, Gilead Sciences, Inc. (NASDAQ:GILD) and Intuitive Surgical, Inc. (NASDAQ:ISRG) don't make for the most obvious comparison.
Gilead vs. Danaher: Which Healthcare Growth Story is More Convincing?
Gilead Sciences, Inc. (NASDAQ:GILD) and Danaher Corporation (NYSE:DHR) are both showing signs of stronger growth, but they are getting there in very different ways.
10 Best Healthcare Stocks to Buy According to Hedge Funds
Healthcare has rarely been short of investment opportunities, but deciding where to look has become more complicated.
Gilead vs. Thermo Fisher: Which Life Sciences Stock has the Stronger Growth Outlook?
Gilead Sciences, Inc. (NASDAQ:GILD) and Thermo Fisher Scientific Inc. (NYSE:TMO) are benefiting from two very different sources of growth.
